Zihipp is a UK biotech firm which spun out from Imperial College London in 2012. He is well known as a seminal figure in creation of the hormone-based diabetes and obesity treatment market. Zihipp has developed several new peptide drug candidates optimized for obesity and NASH (Non-Alcoholic Steatohepatitis) treatment analogous to appetite suppressing hormones such as oxyntomodulin and peptide YY which have been proven through clinical trials. For example, existing drug treatments for weight loss can take more than a year to produce 10-15% weight loss coupled with at times severe gastrointestinal side effects. The new SanPlena platform serves a major unmet demand for new and innovative treatment options for weight loss.

Source: Ethiopian News December 29, 2021 03:00 UTC